Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viral Replication: Lytic Cycle01:20

Viral Replication: Lytic Cycle

Bacteriophages, or phages, are viruses that specifically infect bacteria. Among them, T-even bacteriophages, such as T4, exhibit a well-characterized lytic replication cycle in Escherichia coli (E. coli). This process ensures the rapid proliferation of the virus while ultimately leading to the destruction of the bacterial host.Attachment and DNA InjectionThe infection process begins with the recognition and binding of the T4 phage to the E. coli cell surface. Tail fibers of the phage...
Viral Replication: Lysogenic Cycle01:16

Viral Replication: Lysogenic Cycle

The lysogenic cycle is a crucial viral replication strategy that allows bacteriophages to persist within host cells without immediately destroying them. This process is primarily observed in temperate phages, such as bacteriophage lambda (λ), which infects Escherichia coli. The cycle allows the viral genome to persist across bacterial generations while keeping host cells viable.Integration of the Viral GenomeUpon infection, bacteriophage lambda attaches to the bacterial surface and injects its...
Lytic Cycle of Bacteriophages01:30

Lytic Cycle of Bacteriophages

Bacteriophages, also known as phages, are specialized viruses that infect bacteria. A key characteristic of phages is their distinctive “head-tail” morphology. A phage begins the infection process (i.e., lytic cycle) by attaching to the outside of a bacterial cell. Attachment is accomplished via proteins in the phage tail that bind to specific receptor proteins on the outer surface of the bacterium. The tail injects the phage’s DNA genome into the bacterial cytoplasm. In the lytic replication...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Newcastle Disease Virus Vaccine Strain H as a Potential Oncolytic Agent in Ovarian Cancer Therapy].

Molekuliarnaia biologiia·2026
Same author

[Intranasal vaccine against COVID-19 based on a recombinant variant of the Sendai virus (Paramyxoviridae: <i>Respirovirus</i>) strain Moscow].

Voprosy virusologii·2023
Same author

COVID-19, Influenza, and Other Acute Respiratory Viral Infections: Etiology, Immunopathogenesis, Diagnosis, and Treatment. Part 2. Other Acute Respiratory Viral Infections.

Molecular genetics, microbiology and virology : Molekulyarnaya genetika, mikrobiologiya i virusologiya·2023
Same author

[Prevalence and molecular genetic characteristics of parenteral hepatitis B, C and D viruses in HIV positive persons in the Novosibirsk region].

Voprosy virusologii·2022
Same author

Reporter Transgenes for Monitoring the Antitumor Efficacy of Recombinant Oncolytic Viruses.

Acta naturae·2022
Same author

COVID-19, Influenza, and Other Acute Respiratory Viral Infections: Etiology, Immunopathogenesis, Diagnosis, and Treatment. Part I. COVID-19 and Influenza.

Molecular genetics, microbiology and virology : Molekulyarnaya genetika, mikrobiologiya i virusologiya·2022

Related Experiment Video

Updated: May 21, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

[Oncolytic poxviruses].

G V Kochneva, G F Sivolobova, K V Iudina

    Molekuliarnaia Genetika, Mikrobiologiia I Virusologiia
    |June 19, 2012
    PubMed
    Summary

    This review explores engineered poxviruses for cancer therapy, focusing on tumor cell lysis, immune response induction, and apoptosis. Modified poxviruses show promise in clinical trials for treating various cancers.

    Area of Science:

    • Oncology
    • Virology
    • Immunology

    Context:

    • Poxviruses are being engineered as oncolytic agents for cancer treatment.
    • Key modifications include virus attenuation and gene insertions to enhance tumor specificity and therapeutic effects.

    Purpose:

    • To review current advancements in the selection and construction of poxviruses for cancer therapy.
    • To discuss strategies for enhancing oncolytic virotherapy efficacy, including virus attenuation and genetic engineering.

    Summary:

    • Poxvirus attenuation via thymidine kinase and viral growth factor gene inactivation increases tumor selectivity.
    • Incorporation of immunomodulatory genes (interleukins, GM-CSF) and tumor-apoptotic genes (p53) enhances therapeutic potential.
    • Combination therapies with prodrugs and angiogenesis inhibitors show encouraging results, with two poxviral strains in Phase III trials.

    More Related Videos

    A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
    09:16

    A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

    Published on: October 30, 2016

    Ex Vivo Infection of Live Tissue with Oncolytic Viruses
    12:08

    Ex Vivo Infection of Live Tissue with Oncolytic Viruses

    Published on: June 25, 2011

    Related Experiment Videos

    Last Updated: May 21, 2026

    Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
    12:42

    Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

    Published on: January 7, 2019

    A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
    09:16

    A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

    Published on: October 30, 2016

    Ex Vivo Infection of Live Tissue with Oncolytic Viruses
    12:08

    Ex Vivo Infection of Live Tissue with Oncolytic Viruses

    Published on: June 25, 2011

    Impact:

    • Engineered poxviruses offer a novel approach to cancer treatment, inducing antitumor immunity and apoptosis.
    • Genetic modifications improve virus specificity for tumor cells, minimizing off-target effects.
    • Ongoing clinical trials indicate significant potential for poxviruses in oncotherapy.